Suven Life Sciences gains on receiving patents

The company has received one product patent from Mexico and one from Singapore for new chemical entities to treat neuro-degenerative diseases.

Suven Life Sciences Ltd has firmed up on the bourses after receiving one product patent from Mexico and one product patent from Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.

The stock is trading at Rs 318, higher by Rs 4 or 1.2%, on the BSE.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD), the company said in a filing to the BSE. These patents are valid through 2029.

With these new patents, Suven has a total of eighteen granted patents from Mexico and twenty granted patents from Singapore. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts, the company pointed out, adding that products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

The shares had opened at Rs 310 and have touched a low of Rs 309 and a high of Rs 319 thus far.

Suven Life Science is a bio-pharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products.